APO-BIMATOPROST

USDailyMed:Bimatoprost AU:B3 S01EE03(WHO) AU:S4(Prescription only)US:℞-onlyEU:Rx-only 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)- cyclopentyl]-N-ethyl-hept-5-enamide 155206-00-1Y 5311027 1958 DB00905Y 4470565Y QXS94885MZ D02724N CHEBI:51230Y ChEMBL1200963N DTXSID30895042 Interactive image CCNC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCc1ccccc1 InChI=1S/C25H37NO4/c1-2-26-25(30)13-9-4-3-8-12-21-22(24(29)18-23(21)28)17-16-20(27)15-14-19-10-6-5-7-11-19/h3,5-8,10-11,16-17,20-24,27-29H,2,4,9,12-15,18H2,1H3,(H,26,30)/b8-3-,17-16+/t20-,21+,22+,23-,24+/m0/s1YKey:AQOKCDNYWBIDND-FTOWTWDKSA-NY Bimatoprost, sold under the brand nameLumiganamong others, is amedicationused to treathigh pressure inside the eyeincludingglaucoma.Specifically it is used foropen angle glaucomawhen other agents are not sufficient.It may also be used to increase the size of theeyelashes.It is used as an eye drop and effects generally occur within four hours. Common side effects include red eyes, dry eyes, change in color of the eyes, blurry vision, andcataracts.Use duringpregnancyorbreastfeedingis generally not recommended.It is aprostaglandinanalog and works by increasing the outflow ofaqueous fluidfrom the eyes. Bimatoprost was approved for medical use in the United States in 2001.It is available as ageneric medication.In 2023, it was the 238th most commonly prescribed medication in the United States, with more than 1million prescriptions.